Target-Directed Approaches for Screening Small Molecules against RNA Targets.
Haniff HS, Knerr L, Chen JL, Disney MD, Lightfoot HL.
SLAS Discov. 2020 Sep;25(8):869-894. doi: 10.1177/2472555220922802. Epub 2020 May 18.
Emerging Targets in Non-Small Cell Lung Cancer.
Liu L, Soler J, Reckamp KL, Sankar K.
Int J Mol Sci. 2024 Sep 18;25(18):10046. doi: 10.3390/ijms251810046.
Chasing molecular glue degraders: screening approaches.
Domostegui A, Nieto-Barrado L, Perez-Lopez C, Mayor-Ruiz C.
Chem Soc Rev. 2022 Jul 4;51(13):5498-5517. doi: 10.1039/d2cs00197g.
Genome engineering with zinc-finger nucleases.
Carroll D.
Genetics. 2011 Aug;188(4):773-82. doi: 10.1534/genetics.111.131433.
Targeted Drug Delivery: Trends and Perspectives.
Ashique S, Sandhu NK, Chawla V, Chawla PA.
Curr Drug Deliv. 2021;18(10):1435-1455. doi: 10.2174/1567201818666210609161301.
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T.
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. doi: 10.1038/s41392-020-00449-4.
Targeting the undruggables-the power of protein degraders.
Zhang C, Liu Y, Li G, Yang Z, Han C, Sun X, Sheng C, Ding K, Rao Y.
Sci Bull (Beijing). 2024 Jun 15;69(11):1776-1797. doi: 10.1016/j.scib.2024.03.056. Epub 2024 Mar 29.
Synthetic Lethality in Cancer Therapeutics: The Next Generation.
Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN.
Cancer Discov. 2021 Jul;11(7):1626-1635. doi: 10.1158/2159-8290.CD-20-1503. Epub 2021 Apr 1.
The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I, Verrecchia F, Crenn V, Redini F, Trichet V.
Cells. 2020 Apr 15;9(4):976. doi: 10.3390/cells9040976.
Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer.
Stuchbery R, Kurganovs NJ, McCoy PJ, Nelson CC, Hayes VM, Corcoran NM, Hovens CM.
Curr Cancer Drug Targets. 2015;15(5):394-405. doi: 10.2174/1568009615666150416113453.
